Global Alternate-Site Infusion Therapy Market

MARKET SCOPE:

The global Alternate-Site Infusion Therapy market is projected to grow significantly, registering a CAGR of 7.6% during the forecast period (2024 – 2032).

The term ""Alternate Site Infusion Therapy"" pertains to the method through which patients undergo treatment outside of traditional hospital settings or at home, involving the administration of drugs or biological products. The majority of these therapeutic substances are delivered through a needle or catheter in a process known as infusion. Some medications are also administered through alternative routes. Infusion therapy is typically prescribed for both acute and chronic illnesses that cannot be solely addressed with oral medications. This approach enables patients to have a shorter hospital stay, as infusion therapy can be conveniently provided in alternate-site settings like homes and ambulatory infusion centers.

MARKET OVERVIEW:

Driver: The surging prevalence of diminished mobility among the baby boomer demographic is driving the market growth.

The expansion of the alternate site infusion therapy market is driven by the increasing prevalence of diminished mobility among the baby boomer demographic, attributed to conditions like osteoarthritis and diabetes. With the aging of the baby boomer generation, there is a noticeable rise in health issues linked to reduced mobility. The higher incidence of chronic conditions, particularly osteoarthritis and diabetes, within this demographic has generated a heightened demand for infusion therapy.

Moreover, the significant growth in the geriatric population is a contributing factor to the expansion of the alternate site infusion therapy market. Older adults often confront multiple health challenges, and the convenience and adaptability provided by alternate site infusion therapy, including treatments at home or in ambulatory infusion centers, align seamlessly with the requirements of this demographic. These alternative settings for infusion therapy offer a more patient-friendly and easily accessible approach, addressing the specific healthcare needs of the aging population.

Opportunities: - The increasing preference for home care and alternative site care and rising need to decrease the duration of inpatient stays are expected to pave the way for market growth in the upcoming years.

The increasing preference for home care and alternative site care, along with the growing imperative to reduce inpatient stays, significantly contributes to market growth across diverse healthcare sectors. Many individuals express a preference for receiving medical care in the familiar environment of their homes. Home care not only supports emotional well-being but also enhances overall comfort. By avoiding hospital stays, home care minimizes the stress and disruption typically associated with medical facilities. Patients can adhere to their daily routines, fostering a more normalized lifestyle. Moreover, home care often entails a more personalized approach from healthcare professionals, nurturing a stronger patient-caregiver relationship. In addition to home care, alternative site care, encompassing ambulatory care centers and outpatient facilities, provides flexibility in scheduling appointments and treatments. This flexibility is particularly advantageous for patients managing chronic conditions that necessitate regular medical attention. The shift towards providing care in alternative settings offers accessibility benefits and has the potential for significant cost savings for both patients and healthcare providers. This financial aspect is especially pertinent as the healthcare industry actively explores strategies to enhance the cost-effectiveness of services.

COVID IMPACT:

As the number of COVID-19 cases surged in 2020, there was a heightened demand for alternate site solutions, and providers offering home and specialty infusion services played a crucial role in supporting patients. Nevertheless, key market players' strategic initiatives were anticipated to further drive market growth. For instance, in July 2021, Eitan Medical established a new office in Germany for the DACH region to broaden its customer base. The EU MDR certification of its Sapphire infusion system allowed it to cater to clinicians in hospitals and home care settings across Europe, delivering a diverse range of therapies for various clinical use cases. In a similar vein, in January 2021, Amedisys partnered with Option Care Health to provide COVID-19 infusion therapy to the vulnerable population. Consequently, these proactive measures were expected to contribute to the expansion of the market.

SEGMENTATION ANALYSIS:

The anti-infective therapy is anticipated to grow significantly during the forecast period.

The global alternate-site infusion therapy market is anticipated to be predominantly led by the anti-infective therapy segment throughout the forecast period. Among the various alternate-site infusion therapies, anti-infective therapy stands out as one of the most frequently prescribed. However, this therapeutic approach comes with inherent risks, which can be mitigated through a collaborative team approach, meticulous patient selection criteria, a well-structured follow-up process, and a strong emphasis on patient education. Several factors contribute to the growth of the infectious disease drugs market. These include heightened awareness initiatives by government and non-profit organizations, a growing prevalence of infectious diseases, and increased funding and research and development activities. Notably, data from the World Health Organization (WHO) Global Tuberculosis Report 2021 reveals that a significant portion of tuberculosis cases is concentrated in the WHO regions of South-East Asia (43%), Africa (25%), and the Western Pacific (18%). Additionally, WHO data from 2021 indicates that Sub-Saharan Africa bears a substantial burden of malaria, with 95% of all infections occurring in this region. Consequently, the escalating prevalence of various infectious diseases in both developed and emerging markets is expected to propel market growth.

REGIONAL ANALYSIS:

The North American region is set to witness significant growth during the forecast period.

North America emerges as a key region in the home infusion therapy market, driven by various factors including the escalating prevalence of chronic diseases, treatment costs, technological advancements, and ongoing product launches that collectively contribute to regional growth. An illustration of this is reflected in the 2021 updates from the American Cancer Society, estimating approximately 1.8 million new cancer cases reported in the United States alone in 2020. Notably, prevalent malignancies in the U.S. encompass breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, and skin cancer. The migration from acute care to home care settings is gaining momentum due to cost-effectiveness and improved patient mobility, further fueling regional expansion. Advancements in the healthcare industry and the utilization of increasingly sophisticated medical items also boost the demand for regional healthcare products.

COMPETITIVE ANALYSIS

The global Alternate-Site Infusion Therapy market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.

KORU Medical Systems

• In January 2023, KORU Medical Systems, Inc. has established a development agreement with a pharmaceutical manufacturer specializing in subcutaneous immunoglobulin therapy (SCIg). The collaboration aims to develop and pursue regulatory approval for the Freedom Infusion System, which will incorporate a prefilled syringe specifically designed for SCIg. The existing components of the Freedom Infusion System, such as the Freddom60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets, are currently utilized for infusions administered in home and alternate care settings.

McLaren

Option Care Health

Coram CVS

HCA Healthcare

PharMerica

CHI Health

Accredo Health

UnitedHealth Group

Cleveland Clinic

B. Braun Melsungen AG

Scope of the Report

By Product Type

Chemotherapy

Anti-Infective Therapies

Immune Therapy

General Nursing Services

Others

By Disease

Cancer

Chronic Disease

By Application

Residential

Ambulatory Infusion Centers

Others

By Region

North America (the United States & Canada)

Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)

Rest of the World (the Middle East & Africa, Latin America, and Rest of The World)

Keys reasons to purchasing this report

It provides a technological development map over time to understand the industry’s growth rate and indicates how the Alternate-Site Infusion Therapy market is evolving.

The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Alternate-Site Infusion Therapy submarket will be the main driver of the overall market from 2024 to 2032.

It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.

It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.